Peloton priced shares at $29 after the bell Wednesday, valuing the company at $8.06 billion as it prepares to make its public debut Thursday. That's at the high end of the original $26 to $29 price range Peloton was targeting. The company raised $1.16 billion in the offering.
Peloton is pitching itself to investors as more than just an at-home fitness company. With live and on-demand classes led by popular instructors, plus branded gear and clothing that members can flaunt in public, Peloton is hoping its cult-like following translates to a successful IPO.
Peloton boasts a loyal subscriber-base with over 1.4 million members that logged 55 million total workouts in fiscal 2019. In its S-1 filing, Peloton also said it had a 95 percent member retention rate which helped the company rake in $915 million in revenue. Most of that money came from sales of Peloton's high-margin and high-cost Connected Fitness Products.
The Peloton bike costs about $2,000 and its treadmill more than $4,000. The Connected Fitness Subscription, which allows members to stream classes for $39 a month, accounted for nearly 20 percent of Peloton's revenue for fiscal 2019.
Those classes are only getting more popular. Peloton says the average number of monthly workouts per connected subscriber has about doubled since the first quarter of 2017 to more than 12 workouts a month.
Still, losses for the company are widening. Peloton's annual net loss more than quintupled from $47.9 million in fiscal 2018 to $245.7 million in 2019. The company doesn't expect to achieve profitability in the near future.
Another reason that may give investors pause, Peloton is currently facing a $300 million lawsuit over the use of music streamed in its classes. The National Music Publisher's Association claims tracks from big-time artists like Taylor Swift, Adele, and the Beatles, have been used unlawfully. Peloton has spent $50.6 million on music licensing over the last three years.
Peloton will start trading Thursday on the Nasdaq Exchange under the ticker symbol PTON.
Paramount Global is set to absorb Showtime into Paramount+, creating a single streaming option to compete with the likes of Netflix and Warner Bros. Discovery’s Max. The company also plans to raise the monthly price from $9.99 to $11.99 per month after the integration.
Debt ceiling talks are underway in Washington, DC ahead of a default deadline. Michael Rosen, chief investment officer with Angeles Investments, joined Cheddar News to explain how a potential default could affect investment portfolios, among other items, for Americans.
Australia's government announced regulations for buy now, pay later services, which will be labeled as consumer credit products, which puts them under the country's Securities and Investments Commission's watch.
Walmart is reportedly teaming up with pet telehealth provider Pawp, giving subscribers unlimited access to vet services via video and text, starting on Tuesday.
Cheddar News checks in to see what's on The Day Ahead, which will include earnings from Lowe's, Dick's Sporting Goods, BJ's and AutoZone along with new home sales data. In addition, Microsoft's Build 2023 Developer Conference is slated to kick off for software engineers and web developers.
Amazon will use a new feature in its palm-scanning system to verify one's age to purchase alcohol.
Venmo will soon have accounts for teenagers ages 13-17 but they will have to follow a set of rules, with parents or guardians opening accounts on their behalf under their own accounts.
Rory Harvey, General Motors' incoming North American president, joined Cheddar News to discuss GM's foray into the rapidly-changing electric vehicle market along with what lies ahead. "It's a very dynamic time in the automotive industry," he said. "If you look to the transformation across the EVs, it's happening and it's happening at a pace."
Tesla trimmed prices by offering discounts of around $1,300 for its Model 3 vehicles, continuing price adjustments across its fleet since January.
A new oral weight-loss drug from Pfizer could be more effective than the popular Ozempic injection, based on clinical trial results.
